ok i caught the Q&A
1. generic lovenox has slightly greater than 40% market share
2. wouldn't comment on pricing for competitive reasons
3. said that if remain sole generic beyond midyear then their sandoz guidance improves mid-single digit growth to upper single digit growth
on this last point one can try and estimate enox sales based on the differential between mid to upper single digit growth based on sandoz annual sales/earning, relative contribution enox, relative differential in profits between sole generic and multiple over 6 months,..
it also tells me nvs is assuming sole generic through june in their guidance, for whatever that's worth (not sure if NVS tends to be conservative or aggressive with such guidance)
Market Data 
Markets 
AI
